Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood 'bath' with light may stop transplant complication

NCT ID NCT03204721

Disease control Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a procedure called extracorporeal photophoresis (ECP) could prevent graft-versus-host disease (GVHD) in 158 people receiving stem cell transplants for blood cancers. ECP involves removing white blood cells, treating them with a light-sensitive drug and UV light, then returning them to the patient. The goal was to see if this could lower the chance of GVHD, a serious complication where donor cells attack the patient's body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
extracorporeal photophoresis (ECP) with 8-methoxypsoralen and ultraviolet A light
What this could lead to
If it works, ECP could become a standard preventive treatment to reduce the risk of graft-versus-host disease after stem cell transplants.
What could go wrong
This is a completed study, but results are not yet widely confirmed. ECP is a complex procedure and may not work for everyone. The trial was not blinded, which could bias results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

158 people

The number who actually took part.

Started

Jun 2017

Finished

Apr 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provide written consent to participate * Understand Norwegian or English * No previous history of malignant disease * No contraindication to ECP-treatment or undergone previous ECP treatment Exclusion Criteria: * (in addition to those regarding eligibility for transplantation itself): * Unwilling to provide written consent to participate * Unable to cooperate as judged by the responsible physician * ECOG status \> 2 at time of inclusion * Using anti-inflammatory or cytotoxic drugs other than those that are part of the treatment of the current hematological malignancy * Known allergy to psoralens or citrate products * Splenectomy * Pregnancy/lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graft versus host disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graft versus host disease

Contacts and locations

Locations

  • Tobias Gedde-Dhl

    Oslo, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.